Select Publications
Journal articles
2024, 'The phageome of patients with ulcerative colitis treated with donor fecal microbiota reveals markers associated with disease remission', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-53454-4
,2024, 'Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial', Clinical Gastroenterology and Hepatology, 22, pp. 2299 - 2308.e5, http://dx.doi.org/10.1016/j.cgh.2024.04.019
,2024, 'Refining microbial community metabolic models derived from metagenomics using reference-based taxonomic profiling', mSystems, 9, http://dx.doi.org/10.1128/msystems.00746-24
,2024, 'Key metabolomic alterations are associated with ulcerative colitis disease state and activity: A validation analysis', Gut, 73, pp. 1392 - 1393, http://dx.doi.org/10.1136/gutjnl-2023-330196
,2023, 'Microbial determinants of effective donors in faecal microbiota transplantation for UC', Gut, 72, pp. 90 - 100, http://dx.doi.org/10.1136/gutjnl-2022-327742
,2022, 'Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply', The Lancet Gastroenterology and Hepatology, 7, pp. 286 - 287, http://dx.doi.org/10.1016/S2468-1253(22)00045-0
,2022, 'Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial', The Lancet Gastroenterology and Hepatology, 7, pp. 141 - 151, http://dx.doi.org/10.1016/S2468-1253(21)00400-3
,2021, 'Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy', Gut, 70, pp. 2210 - 2211, http://dx.doi.org/10.1136/gutjnl-2020-323581
,2021, 'Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy', GUT, 70, pp. 2210 - 2210, http://dx.doi.org/10.1136/gutjnl-2020-323581
,2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab', Medical Journal of Australia, 215, pp. 435, http://dx.doi.org/10.5694/mja2.51303
,2021, 'Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD', Alimentary Pharmacology and Therapeutics, 53, pp. 1038 - 1039, http://dx.doi.org/10.1111/apt.16325
,2021, 'Long-term bacterial and fungal dynamics following oral lyophilized fecal microbiota transplantation in clostridioides difficile infection', mSystems, 6, http://dx.doi.org/10.1128/MSYSTEMS.00905-20
,2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study', Medical Journal of Australia, 214, pp. 128 - 133, http://dx.doi.org/10.5694/mja2.50824
,2020, 'The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease', Current Opinion in Pharmacology, 55, pp. 8 - 16, http://dx.doi.org/10.1016/j.coph.2020.08.009
,2020, 'Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice', Gut, 69, pp. 801 - 810, http://dx.doi.org/10.1136/gutjnl-2019-320260
,2019, 'Vitamin D metabolites are lower with active Crohn’s disease and spontaneously recover with development of remission', Therapeutic Advances in Gastroenterology, 12, http://dx.doi.org/10.1177/1756284819865144
,2019, 'Safety of drugs used for the treatment of Crohn’s disease', Expert Opinion on Drug Safety, 18, pp. 357 - 367, http://dx.doi.org/10.1080/14740338.2019.1612874
,2018, 'A global survey of gastroenterologists' travel advice to patients with inflammatory bowel disease on immunosuppressive agents and management of those visiting tuberculosis-endemic areas', Journal of Crohn's and Colitis, 12, pp. 1261 - 1269, http://dx.doi.org/10.1093/ecco-jcc/jjy110
,2018, 'Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation', Transplant Infectious Disease, 20, http://dx.doi.org/10.1111/tid.12934
,2018, 'Entyvio lengthen dose-interval study: Lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease', European Journal of Gastroenterology and Hepatology, 30, pp. 735 - 740, http://dx.doi.org/10.1097/MEG.0000000000001150
,2017, 'A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation', Liver Transplantation, 23, pp. 487 - 497, http://dx.doi.org/10.1002/lt.24730
,2015, 'Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation', Liver Transplantation, 21, pp. 1478 - 1485, http://dx.doi.org/10.1002/lt.24216
,